



MEMBRANOUS NEPHROPATHY

NEW INSIGHTS
FROM RESEARCH:
WILL THEY TRANSLATE
INTO HOPE FOR PATIENTS?

MAY 4-5, 2018

**Mario Negri Institute for Pharmacological Research
Clinical Research Center for Rare Diseases "Aldo e Cele Daccò"**

Ranica, Bergamo, Italy

www.membranousnephropathybg.it

FRIDAY MAY 4, 2018

- 08.30 – 09.00 **Registration**
- 09.00 – 09.10 **Welcome and Introduction to Conference**
Ariela Benigni, Italy
- 09.10 – 10.20 **Roundtable 1**
Autoimmunity: Etiology
Moderator: Larry Beck, USA
- 09.10 – 09.30 *Is there a role for bacterial infections?*
Paul E. Brenchley, UK
- 09.30 – 09.50 *Is there a role for environmental exposure?*
Fan Fan Hou, China
- 09.50 – 10.20 *Discussion*
- 10.20 – 10.50 Coffee/Tea Break
- 10.50 – 12.40 **Roundtable 2**
Autoimmunity: Antigenic Targets
Moderator: Rolf Stahl, Germany
- 10.50 – 11.10 *Future directions in the PLA2R research*
Larry Beck, USA
- 11.10 – 11.30 *Epitope Spreading of Autoantibody Response to PLA2R*
Gérard Lambeau, France
- 11.30 – 11.50 *Thrombospondin type-1 domain-containing 7A*
Elion Hoxha, Germany
- 11.50 – 12.10 *Secondary membranous nephropathy and other antigens: a role for immune response against Complement Factor H?*
Pierre Ronco, France
- 12.10 – 12.40 *Discussion*
- 12.40 – 13.00 **Mini Lecture: Membranous nephropathy: everything has changed in the last 10 years but still a lot to do before we sleep**
David Salant, USA
- 13.00 – 14.00 Lunch
- 14.00 – 14.40 **Roundtable 3**
Pathophysiology and Mediators of Injury
Moderator: Ariela Benigni, Italy
- 14.00 – 14.20 *The pathogenic role of T and B cells*
David Klatzmann, France

- 14.20 – 14.40 *The role of anti-PLA2R antibodies: preclinical findings*
Mario Schiffer, Germany
- 14.40 – 15.00 *The role of anti-THSD7A antibodies: preclinical findings*
Nicola Tomas, Germany
- 15.00 – 15.20 *Complement as a mediator of podocyte injury*
Andrey Cybulsky, Canada
- 15.20 – 16.00 *Discussion*
- 16.00 – 16.30 Coffee/Tea Break
- 16.30 – 17.30: **Roundtable 4**
Genetic Studies
Moderator: Marina Noris, Italy
- 16.30 – 16.50 *Identification of new genetic loci by GWAS in membranous nephropathy*
Krzysztof Kiryluk, USA
- 16.50 – 17.10 *Risk and protective HLA-D alleles in idiopathic membranous nephropathy*
Zhao Cui, China
- 17.10 – 17.45 *Discussion*

SATURDAY MAY 5, 2018

- 09.00 – 10.40: Roundtable 5**
Diagnosis
Moderator: Daniel Cattran, Canada
- 09.00 – 09.20 *Anti-PLA2R antibodies or epitope spreading as predictors of response to therapy and relapses*
Piero Ruggenenti, Italy
- 09.20 – 09.40 *Serology-based approaches to membranous nephropathy*
An De Vriese, Belgium
- 09.40 – 10.00 *Immunological signature as markers of successful immunotherapy*
David Wraith, UK
- 10.00 – 10.40 *Discussion*
- 10.40 - 11.00 Coffee/Tea Break
- 11.00 – 13.00 Roundtable 6**
Treatments
Moderator: Jack Wetzels, The Netherlands
- 11.00 – 11.20 *Critical evaluation of novel versus classical therapies*
Daniel Cattran, Canada

- 11.20 – 11.40 *Rituximab, Ofatumumab and plasma cell-targeted approaches*
Giuseppe Remuzzi, Italy
- 11.40 – 12.00 *New anti-complement molecules*
Joshua Thurman, USA
- 12.00 – 12.20 **Mini Lecture: Groundbreaking treatments in autoimmune diseases**
Jonathan Hogan, USA
- 12.20 – 13.00 *Discussion*
- 13.00 - 14.00 Lunch
- 14.00 – 15.30 **Late-Breaking Findings**
Moderator: Daniel Cattran, Canada
(further discussants may propose at the beginning of the conference)
- Remission and recurrence: an update on randomized controlled trial MENTOR*
Fernando Fervenza, USA
- Recurrence in transplantation as a model for pathophysiology*
Luis Quintana, Spain
- Predicting recurrence of membranous nephropathy in transplantation: is the donor the culprit?*
Pierre Ronco, France
- 15.30 – 17.30 **Patients meet the Doctors**
Moderator: Giuseppe Remuzzi, Italy
Discussants: Daniel Cattran, Canada, Pierre Ronco, France, Piero Ruggenenti, Italy
- 17.30 – 18.00 **Concluding keynote lecture**
Open questions and research direction
William Couser, USA
- 18.00 – 18.30 **SUMMING UP**
William Couser, USA
- 18.30 – 19.30 Interlude

With an unrestricted grant of:



FONDAZIONE
INTERNAZIONALE
MENARINI



Additional contributions:



EUROIMMUN
a PerkinElmer company

